EGFR NSCLC Drugs

Jun 22, 2026

Summary Non-small cell lung cancer accounts for ~85% of all lung cancer cases, with incidence rising steadily. The EGFR-mutant NSCLC landscape has progressed from 1st/2nd-generation EGFR TKIs (limited by T790M resistance, poor CNS penetration, and toxicity) to more effective 3rd-generation TKIs, with osimert...

Jun 05, 2026

Summary The EGFR-mutant NSCLC treatment market was valued at USD 6.6 billion in 2025 and is projected to grow at a 7.3% CAGR over the next decade, driven largely by the emergence of targeted biologics and ADCs. The recent approval of Dato-DXd marks a major milestone and is expected to accelerate the adoption...